Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (Q42922693)

11 November 2017

title

Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial (English)

1 reference

11 November 2017

Levetiracetam for levodopa-induced dyskinesia in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial (English)

1 reference

https://api.crossref.org/works/10.1007/S00702-010-0472-X

3 July 2024

1 reference

1 reference

1 reference

1 reference

1 reference

6

Heinz Reichmann

1 reference

11 November 2017

Martin Wolz

1

1 reference

11 November 2017

Matthias Löhle

2

1 reference

11 November 2017

Karl Strecker

3

1 reference

11 November 2017

Uta Schwanebeck

4

1 reference

11 November 2017

Christine Schneider

5

1 reference

11 November 2017

Xina Grählert

7

1 reference

11 November 2017

Johannes Schwarz

8

1 reference

11 November 2017

Alexander Storch

9

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20803300

3 July 2024

publication date

29 August 2010

1 reference

full work available at URL

11 November 2017

http://link.springer.com/content/pdf/10.1007/s00702-010-0472-x.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00702-010-0472-X

http://link.springer.com/article/10.1007/s00702-010-0472-x/fulltext.html

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00702-010-0472-X

http://link.springer.com/content/pdf/10.1007/s00702-010-0472-x

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S00702-010-0472-X

Journal of Neural Transmission

3 July 2024

published in

1 reference

11 November 2017

volume

117

1 reference

11 November 2017

issue

11

1 reference

11 November 2017

page(s)

1279-1286

1 reference

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00702-010-0472-X

Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-010-0472-X

Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-010-0472-X

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00702-010-0472-X

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Long-term results of bilateral pallidal stimulation in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Levodopa-induced dyskinesias

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

German version of the Epworth Sleepiness Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Efficacy and safety of high-dose cabergoline in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Clinical pharmacokinetics of levetiracetam

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

L-dopa therapy for Parkinson's disease: past, present, and future

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD).

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Low-dose olanzapine for levodopa induced dyskinesias

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Treatment of levodopa-induced motor complications

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Entacapone in the treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Levodopa-dyskinesia incidence by age of Parkinson's disease onset

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

1 reference

https://pubmed.ncbi.nlm.nih.gov/20803300

12 December 2020

45

47

S131

JL Vitek

2000

1 reference

https://api.crossref.org/works/10.1007/S00702-010-0472-X

3 July 2024

Identifiers

1 reference

Dimensions Publication ID

11 November 2017

1048473018

0 references

1 reference